Debiopharm Innovation Fund

What Debiopharm Innovation Fund does

Debiopharm Innovation Fund S.A. is the strategic corporate venture arm of Debiopharm, a privately-held Swiss biopharmaceutical group founded in 1979 by Dr. Rolland-Yves Mauvernay and headquartered in Lausanne. The fund invests in early- and growth-stage digital health and smart data startups, positioning portfolio companies to leverage Debiopharm's broader drug development and commercialization infrastructure. Recent disclosed investments include a co-led $6M seed in Altis Labs (AI-powered clinical trial imaging) and a follow-on investment in ViewsML's $4.9M seed (AI-powered virtual biomarker staining).

Debiopharm's underlying technological base consists of proprietary antibody-drug conjugate platforms—MultiLINK (a cleavable, high-DAR linker supporting multidrug attachment), AbYlink (Fc-selective antibody conjugation in under one hour), and MLINK Duo (dual-payload ADC technology with DAR up to 8+8)—together with a clinical pipeline including Debio 1562M (CD37 ADC, Phase 1/2 for AML), zedoresertib (WEE1 inhibitor), lunresertib (PKMYT1 inhibitor licensed from Repare in July 2025), and afabicin (antibiotic). The fund earns returns through equity upside on portfolio exits and indirectly supports the parent's licensing-royalty revenue model by sourcing digital technologies complementary to Debiopharm's therapeutic pipeline.

The fund operates within a group of three Debiopharm entities (International for drug development, Research & Manufacturing for production, and the Innovation Fund for digital health investment), all under parent company Après-demain SA. Revenue mechanics are not separately disclosed for the fund; group-level revenue is implied by long-running out-licensing of two standards-of-care products (Triptorelin franchise and Eloxatin/oxaliplatin), supplemented by recent deal economics such as the $10M upfront from Repare and up to $267M in potential milestones.

Name

Debiopharm Innovation Fund

Legal name

Debiopharm Innovation Fund S.A.

Website

https://debiopharm.com

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

1–10 employees

Short description

Debiopharm Innovation Fund is the strategic corporate venture arm of Swiss biopharmaceutical group Debiopharm, investing in early- and growth-stage digital health and AI-driven healthcare startups while leveraging the parent's proprietary ADC technology platforms and drug development infrastructure to support portfolio commercialization.

Ownership category

akta.pro rank

Product category

Venture Capital / Digital Health Investment

NAICS

Open-End Investment Funds (525910), Open-End Investment Funds (52591)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

akta.pro secondary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Venture capital funding
• Digital health investment
• Biotech startup funding
• Healthcare venture capital
• Equity capital investment

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Investment Returns: The fund generates returns through equity investments in portfolio companies developing digital health and smart data technologies. Returns are realized through exits via IPOs, acquisitions, or secondary sales when portfolio companies achieve commercial success or are acquired by larger pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Debiopharm Innovation Fund is the corporate venture capital arm of Debiopharm, making strategic equity investments in early-stage digital health and smart data startups. The fund provides capital alongside the parent company's 45+ years of pharmaceutical R&D expertise, linker technology platforms, and access to large-pharmaceutical commercialization partners, targeting pre-seed and seed rounds typically of $4–6 million in North America and Europe.

Product overview

Debiopharm Innovation Fund is the strategic investment arm of Debiopharm, a Swiss biopharmaceutical company with over 45 years of experience developing therapies for oncology and bacterial infections. The parent company's core products include Decapeptyl/Trelstar/Pamorelin/Triptodur (sustained-release triptorelin formulations for prostate cancer and other indications) and Eloxatin/Elplat (oxaliplatin for colorectal cancer). Debiopharm operates technology platforms including MultiLINK ADC Technology Suite (modular peptide-based linker platform for antibody-drug conjugates with dual-payload capability) and AbYlink (antibody conjugation technology). The clinical pipeline spans small molecules (zedoresertib/WEE1 inhibitor, lunresertib/PKMYT1 inhibitor, afabicin antibiotic) and ADCs (Debio 1562M for AML, Debio 0532 HER3-targeted, Debio 2512 bispecific). The Innovation Fund invests in digital health and AI-driven startups including Altis Labs (Nota imaging platform) and ViewsML (virtual biomarker technology).

Differentiator

Problem solved

Functional benefit

Products and services

• Strategic Equity Investment Fund (Digital Health & Smart Data) Strategic equity investment program for early-stage digital health and smart data startups, providing capital alongside the parent group's pharmaceutical R&D expertise and commercialization network. Targets Series A-style and seed-stage rounds, typically $4–6 million per deal, in North America and Europe.
• Portfolio Strategic Support Program Operational and scientific support program accompanying equity investments, providing portfolio companies with access to biopharmaceutical development expertise, proprietary linker technology platforms, and introductions to large-pharmaceutical commercialization partners.

Quantifiable outcome

• Multiple successful portfolio companies including Altis Labs ($6M seed co-led) and ViewsML ($4.9M seed with repeat investment)

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature3 records

Partnerships

Eight partnerships are on record, tiered core.

• PeptroncoreStrategic or Co-development Partner · 24 June 2026Debiopharm and Peptron co-research agreement to develop next-generation ADCs using Peptron's MUC1-targeting antibody PAb001 with Debiopharm's MultiLINK platform. Collaboration evaluates various linker, payload, and conjugation technology combinations to expand PAb001 applicability in ADCs.
• GARDPcoreStrategic or Co-development Partner · 13 January 2026Debiopharm and GARDP (Global Antibiotic Research and Development Partnership) partnered to advance development of a novel gonorrhea drug, addressing critical unmet medical need in antimicrobial resistance.
• NetTargetscoreStrategic or Co-development Partner · 30 October 2025Debiopharm and NetTargets strategic research collaboration combining NetTargets' AI discovery platform with Debiopharm's MLINK Duo technology to rationally design next-generation dual-payload ADCs against drug-resistant cancers. AI identifies synergistic drug pairings for coordinated delivery via MLINK Duo.
• SunRock BiopharmacoreStrategic or Co-development Partner · 21 September 2023Debiopharm partnered with SunRock Biopharma for advancement of antibody drug conjugates targeting hard-to-treat cancers. Debiopharm licensed options to integrate Multilink and AbYlink technologies with SunRock's antibodies against HER2/HER3 and other targets. Partnership extended in January 2024 for HER3-EGFR bispecific ADC development.
• Ubix TherapeuticscoreStrategic or Co-development Partner · 16 June 2021Debiopharm and Ubix Therapeutics co-research agreement to develop Antibody Degraducer Conjugates (ADeC) combining Ubix's Degraducer technology with Debiopharm's Multilink linker platform for improved drug targeting and synergistic effects on tumor cells.
• Genome & CompanycoreStrategic or Co-development PartnerDebiopharm and Genome & Company entered research collaboration for discovery of innovative cancer therapies using antibody-drug conjugates (ADCs). The collaboration combines Genome & Company's novel target-based oncology drug pipeline with Debiopharm's Multilink technology for delivering cytotoxic payloads to tumor cells. Extended in 2024 with exclusive licensing agreement for first-in-class ADC family.
• Oncodesign ServicescoreStrategic or Co-development PartnerStrategic collaboration to propel radiopharmaceuticals in preclinical research, announced April 2025.
• Alkyon TherapeuticscoreStrategic or Co-development PartnerResearch collaboration announced June 2025 to advance next generation radioligand therapies combining Alkyon's expertise with Debiopharm's ADC and radiopharmaceutical capabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/debiopharmfund
• Facebookfacebook.com/pages/Debiopharm-Group/180425588695192
• LinkedInlinkedin.com/company/debiopharminternational

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments36 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Debiopharm Innovation Fund